PriceTargets.com logo

Aditxt - ADTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 344.94%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.90 As of 03/30/2023 01:00 AM ET
▲ +0.01 (1.12%)

This chart shows the closing price for ADTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aditxt Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADTX

Analyst Price Target is $4.00
▲ +344.94% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aditxt in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 344.94% upside from the last price of $0.90.

This chart shows the closing price for ADTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Aditxt. This rating has held steady since October 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/14/2022HC WainwrightInitiated CoverageBuy$4.00Low
9/16/2022Dawson JamesDowngradeBuy ➝ NeutralLow
2/4/2021Dawson JamesInitiated CoverageBuyHigh
(Data available from 3/30/2018 forward)

News Sentiment Rating

1.84 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 5 very positive mentions
  • 30 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
10/1/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Aditxt logo
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Read More

Today's Range

Now: $0.90
Low: $0.89
High: $0.90

50 Day Range

MA: $1.19
Low: $0.85
High: $1.55

52 Week Range

Now: $0.90
Low: $0.83
High: $28.49

Volume

10,758 shs

Average Volume

157,253 shs

Market Capitalization

$3.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Aditxt?

The following Wall Street analysts have issued stock ratings on Aditxt in the last twelve months: Dawson James, and HC Wainwright.
View the latest analyst ratings for ADTX.

What is the current price target for Aditxt?

1 Wall Street analysts have set twelve-month price targets for Aditxt in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 344.9%. HC Wainwright has the highest price target set, predicting ADTX will reach $4.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $4.00 for Aditxt in the next year.
View the latest price targets for ADTX.

What is the current consensus analyst rating for Aditxt?

Aditxt currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADTX will outperform the market and that investors should add to their positions of Aditxt.
View the latest ratings for ADTX.

What other companies compete with Aditxt?

Other companies that are similar to Aditxt include 180 Life Sciences, PLx Pharma, Qualigen Therapeutics, InMed Pharmaceuticals and First Wave BioPharma. Learn More about companies similar to Aditxt.

How do I contact Aditxt's investor relations team?

Aditxt's physical mailing address is 2569 WYANDOTTE ST. SUITE 101, MOUNTAIN CA, 94043. The company's listed phone number is 650-870-1200 and its investor relations email address is [email protected] The official website for Aditxt is www.aditxt.com. Learn More about contacing Aditxt investor relations.